Details

Autor(en) / Beteiligte

• Jabbour, Elias
• Kantarjian, Hagop M.
• Saglio, Giuseppe
• Steegmann, Juan Luis
• Shah, Neil P.
• Boqué, Concepción
• Chuah, Charles
• Pavlovsky, Carolina
• Mayer, Jiří
• Cortes, Jorge
• Baccarani, Michele
• Kim, Dong-Wook
• Bradley-Garelik, M. Brigid
• Mohamed, Hesham
• Wildgust, Mark
• Hochhaus, Andreas

Titel

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Ist Teil von

• Blood, 2014-01, Vol.123 (4), p.494-500

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2014

Link zum Volltext

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with a minimum follow-up of 3 years. Patients with newly diagnosed CML-CP were randomized to receive 100 mg dasatinib (n = 259) or 400 mg imatinib (n = 260) once daily. The retrospective landmark analysis included patients evaluable at the relevant time point (3, 6, or 12 months). Median time to complete cytogenetic response was 3 vs 6 months with dasatinib vs imatinib. At 3 and 6 months, the proportion of patients with BCR-ABL transcript levels ≤10% was higher in the dasatinib arm. Deeper responses at 3, 6, and 12 months were observed in a higher proportion of patients on dasatinib therapy and were associated with better 3-year progression-free survival and overall survival in both arms. First-line dasatinib resulted in faster and deeper responses compared with imatinib. The achievement of an early molecular response was predictive of improved progression-free survival and overall survival, supporting new milestones for optimal response in patients with early CML-CP treated with tyrosine kinase inhibitors. This study was registered at www.clinicaltrials.gov as NCT00481247. •In a 3-year follow-up of the DASatinib versus Imatinib Study In treatment-Naive CML patients trial, first-line dasatinib resulted in faster and deeper responses compared with imatinib.•Deeper responses at 3, 6, and 12 months were associated with better 3-year progression-free survival and overall survival.